AI-generated research brief — verify at source
Phase III Trial Finds Mistletoe Extract Provides No Quality-of-Life Benefit in Advanced Pancreatic Cancer
A double-blind, placebo-controlled phase III trial enrolling 290 patients found no statistically significant improvement in health-related quality of life, body weight, supportive care costs, or blood biomarkers with subcutaneous mistletoe extract compared to placebo in advanced pancreatic cancer. The findings were consistently neutral across all primary and exploratory endpoints, with the sole exception of a pharmacologically expected but clinically inconsequential rise in eosinophil counts in the mistletoe arm.
What Was Studied
The MISTRAL trial investigated whether subcutaneous mistletoe extract, administered alongside standard treatment, could improve health-related quality of life, body weight, healthcare resource utilization, and blood biomarker profiles in patients with advanced pancreatic cancer — a disease associated with markedly poor quality of life and limited options for meaningful symptomatic relief. Quality of life was assessed using the validated EORTC-QLQ-C30 and disease-specific EORTC-QLQ-PAN26 instruments, providing a rigorous, multidimensional primary outcome.
How It Was Studied
MISTRAL was an investigator-initiated, phase III, randomized, double-blind, placebo-controlled, parallel-group superiority trial conducted across nine oncology centers, with a nested biomarker substudy. A total of 290 participants with advanced pancreatic cancer and an Eastern Cooperative Oncology Group performance status of 0–2 were enrolled; patients with neuroendocrine pancreatic tumors were excluded. Participants received either subcutaneous mistletoe extract or placebo added to their standard treatment, which comprised either palliative chemotherapy or best supportive care depending on individual clinical circumstances. Assessments were conducted from baseline through nine months of follow-up, covering quality of life, body weight, cost-related parameters, and a panel of blood biomarkers.
What Was Observed
- No quality-of-life benefit was detected. Scores on both the EORTC-QLQ-C30 and the pancreatic cancer-specific EORTC-QLQ-PAN26 showed no statistically significant differences between the mistletoe and placebo arms at any assessment point across the nine-month follow-up. Body weight likewise did not differ meaningfully between groups.
- Healthcare resource use was equivalent across arms. Observed cost parameters — including days of inpatient hospitalization, parenteral nutrition infusions, nutritional supplement consumption, palliative home care visits, and symptom-relieving medication use — were similar between treatment groups, rendering a formal cost comparison unnecessary and non-informative.
- Blood biomarkers showed no clinically relevant differences. Exploratory biomarker analyses covering differential blood count, lymphocyte subpopulations, C-reactive protein, albumin, and CA19-9 revealed no significant between-group changes, with one exception: eosinophil counts were statistically significantly elevated in the mistletoe arm, a finding that carried no discernible clinical association or outcome relevance.
Why This Matters
Mistletoe extract is one of the most widely used complementary therapies among cancer patients, frequently promoted for quality-of-life improvement, yet robust phase III evidence in specific cancer populations has been limited. MISTRAL directly addresses this gap in advanced pancreatic cancer — a setting where symptom burden is high and effective palliative interventions are urgently needed. The trial’s findings provide high-quality evidence that mistletoe extract does not fulfill its proposed role in this population, and the authors explicitly state that no clinical basis exists to recommend its use in this context.
How to Read This Result
Although the MISTRAL trial is methodologically strong — phase III, double-blind, multicenter, with validated quality-of-life instruments — the abstract does not report quantitative effect sizes or confidence intervals for the primary outcome, which limits the ability to assess the precision of the null findings or rule out small but potentially meaningful differences with certainty.
Limitations
The trial was conducted exclusively in patients with advanced pancreatic cancer, so the results cannot be extrapolated to other cancer types in which mistletoe extract is used. Additionally, because cost-related parameters were equivalent between arms, a formal health economic analysis was not undertaken, leaving questions about the cost-effectiveness of mistletoe extract in broader palliative oncology settings unanswered.